| Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma JD Hintzsche, NT Gorden, CM Amato, J Kim, KE Wuensch, SE Robinson, ... Melanoma research 27 (3), 189-199, 2017 | 141 | 2017 |
| The mutational landscape of mucosal melanoma KW Nassar, AC Tan Seminars in cancer biology 61, 139-148, 2020 | 139 | 2020 |
| MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells N Mukherjee, J Skees, KJ Todd, DA West, KA Lambert, WA Robinson, ... Cell death & disease 11 (6), 443, 2020 | 51 | 2020 |
| Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer TC Beadnell, KW Nassar, MM Rose, EG Clark, BP Danysh, MC Hofmann, ... Oncogenesis 7 (2), 23, 2018 | 44 | 2018 |
| Targeting the NF-κB pathway as a combination therapy for advanced thyroid cancer N Pozdeyev, A Berlinberg, Q Zhou, K Wuensch, H Shibata, WM Wood, ... PloS one 10 (8), e0134901, 2015 | 39 | 2015 |
| The mitogen-activated protein kinase pathway facilitates resistance to the src inhibitor dasatinib in thyroid cancer TC Beadnell, KM Mishall, Q Zhou, SM Riffert, KE Wuensch, BE Kessler, ... Molecular cancer therapeutics 15 (8), 1952-1963, 2016 | 31 | 2016 |
| Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma KW Nassar, JD Hintzsche, SM Bagby, V Espinoza, C Langouët-Astrié, ... Molecular cancer therapeutics 20 (10), 2049-2060, 2021 | 19 | 2021 |
| Pre-treatment mutational and transcriptomic landscape of responding metastatic melanoma patients to anti-PD1 immunotherapy CM Amato, JD Hintzsche, K Wells, A Applegate, NT Gorden, VM Vorwald, ... Cancers 12 (7), 1943, 2020 | 19 | 2020 |
| Trunk or branch? Identifying and targeting intratumoral heterogeneity in hepatocellular carcinoma using genomics and patient derived primary cancer cells KE Wuensch, AC Tan Translational Cancer Research 5 (Suppl 7), 2016 | 2 | 2016 |
| Abstract PO3-26-01: Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Kα H1047R mutant-selective inhibitor AC Smith, B Arwood-Levine, A Born, R Brizendine, P Chatterjee, ... Cancer Research 84 (9_Supplement), PO3-26-01-PO3-26-01, 2024 | | 2024 |
| AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition MM Rose, KW Nassar, V Sharma, RE Schweppe Medical Oncology 40 (10), 299, 2023 | | 2023 |
| Chemokine Receptor 1 and its associated immune pathway are downregulated in SF3B1MT blood and non-blood cancers M Dastpak, H Kim, CL Paraggio, CE Leonard, S Yin, B Chi, KW Nassar, ... bioRxiv, 2022.03. 31.485699, 2022 | | 2022 |
| Defining Oncogenic Drivers in Therapy Resistant Melanoma and Rare Melanoma Subtypes KW Nassar University of Colorado Denver, Anschutz Medical Campus, 2021 | | 2021 |
| 674 The effective killing of the difficult-to-treat melanomas with the combinations of MCL1 inhibitors S63845/MIK665 plus Navitoclax N Mukherjee, J Skees, K Todd, D West, K Lambert, W Robinson, C Amato, ... Journal of Investigative Dermatology 140 (7), S91, 2020 | | 2020 |
| Abstract B076: Uncoupling of the cell cycle pathway from the MAPK pathway in BRAF/MEK inhibitor resistant melanoma KW Nassar, J Hintzsche, S Bagby, C Langouet-Astrie, J Samson, C Amato, ... Molecular Cancer Therapeutics 18 (12_Supplement), B076-B076, 2019 | | 2019 |
| Targeting Hsp90 in Thyroid Cancer K Wuensch, TC Beadnell, Q Zhou, KM Mishall, LA Pike, RE Schweppe Thyroid Hormone Action, Cancer and Clinical Thyroid, THR-062-THR-062, 2015 | | 2015 |
| The NF-kappa b Pathway Is Activated By Chemotherapy and Radiation in Thyroid Cancer N Pozdeyev, WM Wood, LA Pike, K Wuensch, H Shibata, BR Haugen ENDOCRINE REVIEWS 35 (3), 2014 | | 2014 |
Aik Choon TanHuntsman Cancer Institute, University of UtahVerified email at hci.utah.edu
